Literature DB >> 12154319

Polymorphic forms of cilostazol.

Linda B Whittall1, Robert R Whittle, Grayson W Stowell.   

Abstract

Two unique conformational polymorphic forms of the compound 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one (cilostazol), C(20)H(27)N(5)O(2), have been discovered and characterized using single-crystal X-ray structural analysis. A third polymorph also exists, but acceptable crystals could not be obtained. Features of both reported polymorphic structures include a chair conformation of the cyclohexyl ring and puckering in the quinolinone ring. The major feature distinguishing the two polymorphic forms is a rotational twisting of the butoxy chain between the tetrazole and quinolinone rings. This difference in conformation influences the intermolecular forces, and hence the packing of the two molecules during crystallization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12154319     DOI: 10.1107/s0108270102012544

Source DB:  PubMed          Journal:  Acta Crystallogr C        ISSN: 0108-2701            Impact factor:   1.172


  3 in total

1.  A systematic approach to design and prepare solid dispersions of poorly water-soluble drug.

Authors:  Sanjay Verma; Varma S Rudraraju
Journal:  AAPS PharmSciTech       Date:  2014-02-22       Impact factor: 3.246

2.  Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.

Authors:  Sanjay Verma; Varma S Rudraraju
Journal:  AAPS PharmSciTech       Date:  2015-02-12       Impact factor: 3.246

3.  An oral formulation of cilostazol nanoparticles enhances intestinal drug absorption in rats.

Authors:  Chiaki Yoshioka; Yoshimasa Ito; Noriaki Nagai
Journal:  Exp Ther Med       Date:  2017-10-24       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.